Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants

Clin Pharmacol Ther. 2006 Jul;80(1):7-12. doi: 10.1016/j.clpt.2006.04.008.
No abstract available

Publication types

  • Review
  • Comment

MeSH terms

  • Acenocoumarol / administration & dosage
  • Acenocoumarol / pharmacokinetics
  • Acenocoumarol / pharmacology*
  • Administration, Oral
  • Anticoagulants / administration & dosage
  • Anticoagulants / pharmacokinetics
  • Anticoagulants / pharmacology*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Cytochrome P-450 CYP2C9
  • Genotype
  • Humans
  • Mixed Function Oxygenases / antagonists & inhibitors
  • Mixed Function Oxygenases / genetics*
  • Vitamin K Epoxide Reductases
  • Warfarin / administration & dosage
  • Warfarin / pharmacokinetics
  • Warfarin / pharmacology*

Substances

  • Anticoagulants
  • Warfarin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Vitamin K Epoxide Reductases
  • Acenocoumarol